Boston Partners
TEVA icon

Boston Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Boston Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,415
Closed -$406K – 766
2024
Q4 		$406K Sell
18,415
-93,117
-83% -$1.69M ﹤0.01% 661
2024
Q3 		$2.01M Buy
111,532
+55,252
+98% +$967K ﹤0.01% 511
2024
Q2 		$915K Buy
56,280
+27,224
+94% +$419K ﹤0.01% 596
2024
Q1 		$410K Sell
29,056
-191,202
-87% -$2.41M ﹤0.01% 718
2023
Q4 		$587K Buy
+220,258
New +$2.06M ﹤0.01% 595
2019
Q1 		– Sell
-176,478
Closed -$2.72M – 723
2018
Q4 		$2.72M Buy
+176,478
New +$3.62M ﹤0.01% 497
2017
Q3 		– Sell
-141,852
Closed -$4.71M – 781
2017
Q2 		$4.71M Buy
141,852
+34,846
+33% +$1.08M 0.01% 484
2017
Q1 		$3.43M Sell
107,006
-1,497,174
-93% -$51.1M ﹤0.01% 566
2016
Q4 		$58.2M Sell
1,604,180
-363,872
-18% -$14.5M 0.08% 212
2016
Q3 		$90.5M Sell
1,968,052
-48,848
-2% -$2.55M 0.13% 184
2016
Q2 		$101M Sell
2,016,900
-2,501,491
-55% -$133M 0.15% 179
2016
Q1 		$242M Buy
4,518,391
+794,272
+21% +$46.6M 0.36% 98
2015
Q4 		$244M Sell
3,724,119
-1,279,172
-26% -$79.1M 0.35% 92
2015
Q3 		$282M Sell
5,003,291
-3,752,147
-43% -$243M 0.43% 66
2015
Q2 		$517M Sell
8,755,438
-238,262
-3% -$14.7M 0.74% 37
2015
Q1 		$560M Sell
8,993,700
-206,302
-2% -$12M 0.83% 32
2014
Q4 		$529M Buy
9,200,002
+1,408,944
+18% +$78.5M 0.79% 33
2014
Q3 		$419M Buy
7,791,058
+4,887,106
+168% +$259M 0.68% 41
2014
Q2 		$152M Buy
2,903,952
+2,789,891
+2,446% +$143M 0.25% 109
2014
Q1 		$6.03M Sell
114,061
-11,631
-9% -$538K 0.01% 488
2013
Q4 		$5.04M Hold
125,692
– – 0.01% 510
2013
Q3 		$4.75M Sell
125,692
-89,456
-42% -$3.49M 0.01% 499
2013
Q2 		$8.43M Buy
+215,148
New +$8.38M 0.02% 372

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Boston Partners's TEVA Position: Q1 2025 in Review

Boston Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 18,415 shares — an estimated $406K sold.

Boston Partners first reported a position in TEVA in Q2 2013 and held it in 23 quarters. The position peaked at $560M in Q1 2015. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Boston Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Boston Partners sold 18,415 Teva Pharmaceuticals shares in Q1 2025, an estimated $406K.
  • Boston Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 23 quarters.
  • Boston Partners's Teva Pharmaceuticals position peaked at $560M in Q1 2015.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Boston Partners's 13F filing for Q1 2025, filed 13 May 2025.